These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
486 related articles for article (PubMed ID: 28426103)
1. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Spain L; Walls G; Julve M; O'Meara K; Schmid T; Kalaitzaki E; Turajlic S; Gore M; Rees J; Larkin J Ann Oncol; 2017 Feb; 28(2):377-385. PubMed ID: 28426103 [TBL] [Abstract][Full Text] [Related]
2. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis. Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531 [TBL] [Abstract][Full Text] [Related]
3. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Menzies AM; Johnson DB; Ramanujam S; Atkinson VG; Wong ANM; Park JJ; McQuade JL; Shoushtari AN; Tsai KK; Eroglu Z; Klein O; Hassel JC; Sosman JA; Guminski A; Sullivan RJ; Ribas A; Carlino MS; Davies MA; Sandhu SK; Long GV Ann Oncol; 2017 Feb; 28(2):368-376. PubMed ID: 27687304 [TBL] [Abstract][Full Text] [Related]
4. Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis. Rangwala HS; Fatima H; Ali M; Sunder S; Devi S; Rangwala BS; Abbas SR J Egypt Natl Canc Inst; 2024 May; 36(1):14. PubMed ID: 38705953 [TBL] [Abstract][Full Text] [Related]
5. Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers. Joseph RW; Shillington AC; Lee TA; Macahilig CP; Diede SJ; Dave V; Harshaw Q; Scherrer E; Liu FX J Med Econ; 2020 Feb; 23(2):132-138. PubMed ID: 31750751 [No Abstract] [Full Text] [Related]
6. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010 [TBL] [Abstract][Full Text] [Related]
7. Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. Shoushtari AN; Friedman CF; Navid-Azarbaijani P; Postow MA; Callahan MK; Momtaz P; Panageas KS; Wolchok JD; Chapman PB JAMA Oncol; 2018 Jan; 4(1):98-101. PubMed ID: 28817755 [TBL] [Abstract][Full Text] [Related]
9. Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy: observational study of 39 patients. Amode R; Baroudjian B; Kowal A; Jebali M; Allayous C; Bagot M; Madjlessi N; Roux J; Viguier M; Basset Seguin N; Porcher R; Pagès C; Lebbé C Melanoma Res; 2017 Apr; 27(2):110-115. PubMed ID: 27926587 [TBL] [Abstract][Full Text] [Related]
10. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. Callahan MK; Kluger H; Postow MA; Segal NH; Lesokhin A; Atkins MB; Kirkwood JM; Krishnan S; Bhore R; Horak C; Wolchok JD; Sznol M J Clin Oncol; 2018 Feb; 36(4):391-398. PubMed ID: 29040030 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials. Hao C; Tian J; Liu H; Li F; Niu H; Zhu B Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143 [TBL] [Abstract][Full Text] [Related]
12. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462 [TBL] [Abstract][Full Text] [Related]
13. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. Xu C; Chen YP; Du XJ; Liu JQ; Huang CL; Chen L; Zhou GQ; Li WF; Mao YP; Hsu C; Liu Q; Lin AH; Tang LL; Sun Y; Ma J BMJ; 2018 Nov; 363():k4226. PubMed ID: 30409774 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163 [TBL] [Abstract][Full Text] [Related]
15. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. Sznol M; Ferrucci PF; Hogg D; Atkins MB; Wolter P; Guidoboni M; Lebbé C; Kirkwood JM; Schachter J; Daniels GA; Hassel J; Cebon J; Gerritsen W; Atkinson V; Thomas L; McCaffrey J; Power D; Walker D; Bhore R; Jiang J; Hodi FS; Wolchok JD J Clin Oncol; 2017 Dec; 35(34):3815-3822. PubMed ID: 28915085 [TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma. Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873 [TBL] [Abstract][Full Text] [Related]
17. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Zimmer L; Apuri S; Eroglu Z; Kottschade LA; Forschner A; Gutzmer R; Schlaak M; Heinzerling L; Krackhardt AM; Loquai C; Markovic SN; Joseph RW; Markey K; Utikal JS; Weishaupt C; Goldinger SM; Sondak VK; Zager JS; Schadendorf D; Khushalani NI Eur J Cancer; 2017 Apr; 75():47-55. PubMed ID: 28214657 [TBL] [Abstract][Full Text] [Related]
18. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma. Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety data for checkpoint inhibitors in advanced melanoma under real-life conditions: A monocentric study conducted in Nice from 2010 to 2016. Taquin H; Fontas E; Massol O; Chevallier P; Balloti R; Beranger G; Lacour JP; Passeron T; Montaudié H Ann Dermatol Venereol; 2018 Nov; 145(11):649-658. PubMed ID: 30098818 [TBL] [Abstract][Full Text] [Related]
20. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]